Gene · 7155
TOP2B: DNA topoisomerase II beta
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TOP2B: DNA topoisomerase II beta. Genes, record 7155. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7155
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q02880 | DNA topoisomerase 2-beta | 1,626 | 21 | Ensembl, GeneID, HGNC |
Source UniProt
Patents18
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4641201 A2 | 2025-10-29 | 1902 | Q02880 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1902 | Q02880 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 8745 | Q02880 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 89214 | Q02880 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 192185 | Q02880 | Espacenet |
| US 10501513 B2 | 2019-12-10 | 8745 | Q02880 | Espacenet |
| JP 2017197545 A | 2017-11-02 | 33446 | Q02880 | Espacenet |
| US 9587003 B2 | 2017-03-07 | 8745 | Q02880 | Espacenet |
| US 9301993 B2 | 2016-04-05 | 8745 | Q02880 | Espacenet |
| US 9255129 B2 | 2016-02-09 | 8745 | Q02880 | Espacenet |
1 to 10 of 18
See all 18 patentsDrugs11
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMSACRINE | CHEMBL43 | DNA topoisomerase II inhibitor | INHIBITOR | ChEMBL |
| BECATECARIN | CHEMBL2107313 | DNA topoisomerase II inhibitor | INHIBITOR | ChEMBL |
| BERUBICIN | CHEMBL2110580 | DNA topoisomerase II inhibitor | INHIBITOR | ChEMBL |
| BERUBICIN HYDROCHLORIDE | CHEMBL2103796 | DNA topoisomerase II inhibitor | INHIBITOR | ChEMBL |
| C-1311 | CHEMBL338604 | DNA topoisomerase II inhibitor | INHIBITOR | ChEMBL |
| DEXRAZOXANE | CHEMBL1738 | DNA topoisomerase II inhibitor | INHIBITOR | ChEMBL |
| DEXRAZOXANE HYDROCHLORIDE | CHEMBL1200778 | DNA topoisomerase II inhibitor | INHIBITOR | ChEMBL |
| ETOPOSIDE | CHEMBL44657 | DNA topoisomerase II inhibitor | INHIBITOR | ChEMBL |
| PAZUFLOXACIN | CHEMBL240163 | DNA topoisomerase II inhibitor | INHIBITOR | ChEMBL |
| TENIPOSIDE | CHEMBL452231 | DNA topoisomerase II inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 11
See all 11 drugsTrials1,444
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07583550 | ETOPOSIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07583511 | ETOPOSIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07583511 | TENIPOSIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07538271 | ETOPOSIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07538258 | ETOPOSIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07525466 | ETOPOSIDE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07510594 | ETOPOSIDE | PHASE2 | ClinicalTrials.gov | |
| NCT07502521 | DEXRAZOXANE | PHASE2 | ClinicalTrials.gov | |
| NCT07498959 | ETOPOSIDE | ClinicalTrials.gov | ||
| NCT07497438 | ETOPOSIDE | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,444
See all 1,444 trialsNIH grants1,317
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TOP2B papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 20 | 2025 |
| ZIABC006161 | DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs | 19 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 16 | 2025 |
| ZIABC006150 | DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs | 16 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 13 | 2025 |
| T32CA009582 | Biochemical and Chemical Training for Cancer Research | 13 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 9 | 2025 |
| R01GM126363 | Mechanistic Studies of Type II Topoisomerases and Topoisomerase-Targeted Agents | 8 | 2025 |
| ZIAES102765 | Structural Biology of Genome Maintenance and DNA repair | 8 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 6 | 2025 |
1 to 10 of 1,317Source NIH's project files
See all 1,317 nih grantsPapers2,315
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Contribution of topoisomerase IIα chromatin-tether and C-terminal domain to mitotic chromosome association and structural organization. | J Cell Sci | 2026 | 42817708 | PubTator, text mining | PubMed |
| JP-1302 inhibits RNA polymerase I transcription and induces nucleolar stress in cancer cell lines. | Cell Death Discov | 2026 | 42816485 | PubTator, text mining | PubMed |
| Integrated Experimental and Computational Investigation of Salicylaldehyde-Derived Imine/Amine Derivatives as Antioxidant and Cytotoxic Agents. | Materials (Basel) | 2026 | 42795203 | PubTator, text mining | PubMed |
| Novel Lomefloxacin-Triazole Hybrids: Design, Synthesis and In Vitro Antiproliferative Activity in Breast, Melanoma and Colon Cancer Cell Lines. | Biomolecules | 2026 | 42793155 | PubTator, text mining | PubMed |
| DNA Topoisomerase IIβ Suppresses Microglial Inflammatory Cytokine Release: A Potential Regulator of Neuroinflammation. | Neurochem Res | 2026 | 42776333 | PubTator, text mining | PubMed |
| Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity. | Cardiovasc Toxicol | 2026 | 42763821 | PubTator, text mining | PubMed |
| Synthesis and in silico studies of hexahydroacridine derivatives as potential antitumor agents. | Sci Rep | 2026 | 42717215 | PubTator, text mining | PubMed |
| HDAC inhibition via suberoylanilide hydroxamic acid ameliorates doxorubicin-induced cardiotoxicity. | Nat Commun | 2026 | 42697879 | PubTator, text mining | PubMed |
| Analysis of gene expression changes upon topobexin treatment and TOP2B-knockout in hiPSC-derived cardiomyocytes. | Biol Open | 2026 | 42489567 | PubTator, text mining | PubMed |
| Optimized CoQ10 delivery via ZnO/CuO nanoparticles: greater in vitro cell cycle arrest and in vivo tumor suppression than unformulated coenzyme Q10. | RSC Adv | 2026 | 42482813 | PubTator, text mining | PubMed |
1 to 10 of 2,315
See all 2,315 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7155
GET https://conductscience.org/api/genes/v1/7155/patents